SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and Veracyte, Inc.

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing operational expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of TG Therapeutics, Inc. and Veracyte, Inc. from 2014 to 2023. Over this period, Veracyte consistently outspent TG Therapeutics, with a peak in 2023 where Veracyte's SG&A expenses were approximately 50% higher than TG Therapeutics. Notably, TG Therapeutics saw a dramatic increase in 2020, with expenses surging by over 400% compared to 2019, reflecting strategic investments or expansions. Meanwhile, Veracyte's expenses grew steadily, peaking in 2023. This trend highlights the differing strategies of these companies in managing their operational costs. Understanding these patterns provides valuable insights into their financial health and strategic priorities, offering a window into how each company navigates the challenges of the biotech industry.